66
Views
6
CrossRef citations to date
0
Altmetric
Miscellany

Effect of 4-Pyridone-3-Carboxamide Ribonucleoside (4PYR)-Potential Cardiovascular Toxin in Perfused Rat Heart

, &
Pages 333-337 | Received 24 Oct 2013, Accepted 02 Dec 2013, Published online: 18 Jun 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Magdalena Zabielska, Barbara Kutryb-Zajac, Paulina Żukowska, Ewa Slominska & Ryszard Smoleński. (2016) Effects of 4-Pyridone-3-carboxamide-1β-D-ribonucleoside on adenine nucleotide catabolism in the aortic wall; Implications for atherosclerosis in ApoE-/-LDLR-/- mice. Nucleosides, Nucleotides & Nucleic Acids 35:10-12, pages 720-725.
Read now

Articles from other publishers (5)

Jyothi Dhuguru, Ryan W. Dellinger & Marie E. Migaud. (2023) Defining NAD(P)(H) Catabolism. Nutrients 15:13, pages 3064.
Crossref
Paulina Mierzejewska, Michal Kunc, Magdalena Agnieszka Zabielska-Kaczorowska, Barbara Kutryb-Zajac, Iwona Pelikant-Malecka, Alicja Braczko, Patrycja Jablonska, Pawel Romaszko, Patrycja Koszalka, Jolanta Szade, Ryszard Tomasz Smolenski & Ewa Maria Slominska. (2021) An unusual nicotinamide derivative, 4-pyridone-3-carboxamide ribonucleoside (4PYR), is a novel endothelial toxin and oncometabolite. Experimental & Molecular Medicine 53:9, pages 1402-1412.
Crossref
Mikhail V. MakarovSamuel A.J. Trammell & Marie E. Migaud. (2019) The chemistry of the vitamin B3 metabolome. Biochemical Society Transactions 47:1, pages 131-147.
Crossref
Iwona Pelikant-Malecka, Ewa Kaniewska-Bednarczuk, Sylwia Szrok, Alicja Sielicka, Maciej Sledzinski, Czesława Orlewska, Ryszard T. Smolenski & Ewa M. Slominska. (2017) Metabolic pathway of 4-pyridone-3-carboxamide-1β-d-ribonucleoside and its effects on cellular energetics. The International Journal of Biochemistry & Cell Biology 88, pages 31-43.
Crossref
Iwona Pelikant-Malecka, Alicja Sielicka, Ewa Kaniewska, Ryszard T. Smolenski & Ewa M. Slominska. (2015) Endothelial toxicity of unusual nucleotide metabolites. Pharmacological Reports 67:4, pages 818-822.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.